Genky Drug Stores - Public Comps and Valuation Multiples

Genky Drug Stores Overview

About Genky Drug Stores

Genky Drug Stores Co Ltd sells beauty and pharmaceutical products.

Founded

1990

HQ

Employees

2.8K+

Website

genky.co.jp

Sectors

Pharmacies

Financials

LTM Revenue $1.4B

LTM EBITDA $112M

EV

$1.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Genky Drug Stores Financials

As of September 2025, Genky Drug Stores reported last 12-month revenue of $1.4B and EBITDA of $112M.

In the same period, Genky Drug Stores generated $281M in LTM gross profit and $48.5M in net income.

See Genky Drug Stores valuation multiples based on analyst estimates

Genky Drug Stores P&L

In the most recent fiscal year, Genky Drug Stores reported revenue of $1.3B and EBITDA of $109M.

Genky Drug Stores expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Genky Drug Stores valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.4B	XXX	$1.3B	XXX	XXX	XXX
Gross Profit	$281M	XXX	$271M	XXX	XXX	XXX
Gross Margin	20%	XXX	20%	XXX	XXX	XXX
EBITDA	$112M	XXX	$109M	XXX	XXX	XXX
EBITDA Margin	8%	XXX	8%	XXX	XXX	XXX
EBIT	$66.6M	XXX	$64.0M	XXX	XXX	XXX
EBIT Margin	5%	XXX	5%	XXX	XXX	XXX
Net Profit	$48.5M	XXX	$46.8M	XXX	XXX	XXX
Net Margin	4%	XXX	4%	XXX	XXX	XXX
Net Debt	XXX	XXX	$186M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Genky Drug Stores including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.4B. EBITDA for the last twelve months was $112M. In the most recent fiscal year, Genky Drug Stores achieved $1.3B in revenue and $109M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.4B	Analyst estimates available to subscribers	$1.3B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$281M	Analyst estimates available to subscribers	$271M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	20.4% gross margin	Analyst estimates available to subscribers	20.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$112M	Analyst estimates available to subscribers	$109M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	8.1% EBITDA margin	Analyst estimates available to subscribers	8.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$66.6M	Analyst estimates available to subscribers	$64.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	4.8% EBIT margin	Analyst estimates available to subscribers	4.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$48.5M	Analyst estimates available to subscribers	$46.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	3.5% net profit margin	Analyst estimates available to subscribers	3.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$186M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Genky Drug Stores

This financial data table provides comprehensive performance metrics for Genky Drug Stores, a company based in Japan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Genky Drug Stores generated $1.4B in revenue over the last twelve months.
The company achieved $112M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $281M.
Net income over the last twelve months reached $48.5M.

Fiscal Year Performance

In the most recent fiscal year, Genky Drug Stores reported $1.3B in total revenue.
Fiscal year EBITDA was $109M.
The company maintained a gross profit margin of 20.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 8.2%.
Net profit margin reached 3.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Genky Drug Stores. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Genky Drug Stores Stock Performance

Genky Drug Stores has current market cap of JPY 143B (or $945M), and EV of JPY 171B (or $1.1B).

Market Cap Evolution

Genky Drug Stores Stock Data

As of October 30, 2025, Genky Drug Stores's stock price is JPY 4695 (or $31).

See Genky Drug Stores trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.1B	$945M	XXX	XXX	XXX	XXX	$1.60

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Genky Drug Stores Valuation Multiples

Genky Drug Stores's trades at 0.9x EV/Revenue multiple, and 11.1x EV/EBITDA.

See valuation multiples for Genky Drug Stores and 15K+ public comps

Genky Drug Stores Financial Valuation Multiples

As of October 30, 2025, Genky Drug Stores has market cap of $945M and EV of $1.1B.

Equity research analysts estimate Genky Drug Stores's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Genky Drug Stores has a P/E ratio of 19.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$945M	XXX	$945M	XXX	XXX	XXX
EV (current)	$1.1B	XXX	$1.1B	XXX	XXX	XXX
EV/Revenue	0.8x	XXX	0.9x	XXX	XXX	XXX
EV/EBITDA	10.1x	XXX	11.1x	XXX	XXX	XXX
EV/EBIT	17.0x	XXX	18.3x	XXX	XXX	XXX
EV/Gross Profit	4.0x	XXX	n/a	XXX	XXX	XXX
P/E	19.5x	XXX	21.3x	XXX	XXX	XXX
EV/FCF	-40.8x	XXX	1120.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Genky Drug Stores Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Genky Drug Stores Margins & Growth Rates

Genky Drug Stores's last 12 month revenue growth is 12%

Genky Drug Stores's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.

Genky Drug Stores's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Genky Drug Stores's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Genky Drug Stores and other 15K+ public comps

Genky Drug Stores Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	12%	XXX	11%	XXX	XXX	XXX
EBITDA Margin	8%	XXX	8%	XXX	XXX	XXX
EBITDA Growth	12%	XXX	12%	XXX	XXX	XXX
Rule of 40	20%	XXX	20%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	38%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	16%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial